Article

Aziz Nazha on Adverse Events Associated With Treatment for MDS

Author(s):

Aziz Nazha

Aziz Nazha, Hematology and Medical Oncology Fellow, Cleveland Clinic, discusses adverse events associated with treatment for myelodysplastic syndrome (MDS).

Aziz Nazha, Hematology and Medical Oncology Fellow, Cleveland Clinic, discusses adverse events associated with treatment for myelodysplastic syndrome (MDS).

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of bald man.
Image of man.
Image of Kumar.
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Melanoma is a key cancer type for developing and testing immunotherapies prior to broader clinical application across other malignancies.
Image of Dr. Kumar.
Photo of a woman with shoulder-length black hair wearing a blazer
Image of a woman wearing a headband and glasses
Image of man.
Related Content
Illustration of blood cell.
April 16th 2025

Bexmarilimab Plus Vidaza Elicit Responses in Myelodysplastic Syndromes

Ryan Scott
Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory higher-risk myelodysplastic syndrome.
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
April 11th 2025

What Role May ctDNA Have in Melanoma Management?

Dr. Michael K. Wong
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
Illustration of woman.
April 8th 2025

Sometimes Cancer is a (Welcome) Distraction

Jane Biehl Ph.D.
In an upside-down, topsy-turvy world, cancer can be a distraction for us.
image of dr. Lillian Siu.
April 3rd 2025

Breaking Down Early Signs and Symptoms of Head and Neck Cancer

Dr Lillian Siu
April is Head and Neck Cancer Awareness Month, and it is important to be aware of early signs and symptoms of the disease, as well as when to seek care.
The EC has approved Rytelo in transfusion-dependent anemia due to very low–, low– or intermediate-risk myelodysplastic syndrome: © Crystal_Light - stock.adobe.com.
March 25th 2025

EU Approves Rytelo for Transfusion-Dependent Anemia in Low-Risk MDS

Ryan Scott
The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or intermediate-risk myelodysplastic syndrome.
Illustration of woman with blonde hair.
March 6th 2025

Looking For The Light After MDS

Jane Biehl Ph.D.
As a cancer survivor, I talk about where to look for the light when in utter darkness.